Venus Remedies Limited Earnings Summary — Q4 FY2026

• Revenue from operations surged 31% YoY to ₹259.40 Cr, marking a multi-year quarterly high.
• The company reported a significant expansion in Q4 EBITDA margins to 21.8%, reflecting improved product mix and pricing power.
• Venus Remedies has successfully transitioned to a near debt-free status, with total borrowings reduced to negligible levels compared to previous cycles.
• The Board recommended a 100% final dividend (₹10 per share), signaling confidence in sustained cash flows.
• Operating cash flow for the full year 2026 reached ₹155.77 Cr, double the prior year's performance.
• Growth is increasingly driven by specialized R&D assets, specifically in Antimicrobial Resistance (AMR) and Oncology segments.
• Non-current investments increased significantly to ₹163.82 Cr, largely reflecting strategic capital allocation toward European subsidiary restructuring.

Management is focusing on a structural shift toward higher-margin products and cost efficiency. The ongoing restructuring of European operations via Venus Pharma GmbH is intended to establish a more robust framework for international marketing authorizations.

Improving

The company has clearly moved past its historical debt-distress phase, showing consistent growth in top-line and a geometric expansion in bottom-line profitability over the last four quarters.

The outlook is positive as the company leverages its portfolio of 135+ patents and 1,040+ marketing authorizations. Increased promoter holding and the move toward becoming an 'Emerging Compounder' suggest long-term stability.